. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Contemp Clin Trials. 2014 Dec 30;41:9–16. doi: 10.1016/j.cct.2014.12.015

Table 2.

Multivariate correlates to being 'very likely' to encourage drug-using partners to participate in a clinical trial for an HCV vaccine (n=356)^a

Characteristic^b	AOR (95% CI)	p-value
Demographic
Male	0.18 (0.08 – 0.37)	<0.001^*
Self-report of being in good health	3.73 (1.70 – 8.16)	0.001^*
HCV seropositive	2.52 (1.29 – 4.92)	0.007^*
Total Monthly Income		0.034^*
First quartile ($0 – $200)	3.77 (1.51 – 9.40)
Second quartile ($201 – $698)	2.74 (1.08 – 6.97)
Third quartile ($699 – $1100)	2.66 (1.04 – 6.81)
Fourth quartile ( ≥ $1101)	Reference
Substance use in past 6 months
Heroin	3.63 (0.80 – 16.50)	0.095
Methamphetamine	1.93 (0.57 – 6.49)	0.288
Network characteristics
Number of network members providing financial support	1.62 (1.05 – 2.49)	0.031^*

AOR: adjusted odds ratio; CI: confidence interval

p-value <0.05

Does not include those who reported that the question was not applicable (n=18) or those who reported no network members (n=59)

All variables were dichotomous with the exception of the continuous variable, "Number of network members providing financial support".